Inhaled corticosteroids
ApprovedSmall molecule
Boehringer IngelheimInhaled corticosteroids is one of 60 small molecule programs targeting Allergic Asthma. It is currently in Approved.
2
Indications
10
Total Trials
1
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Inhaled corticosteroids
Boehringer IngelheimApproved
Veramyst
GSKPreclinical
Xolair
RochePreclinical
Singulair
AstraZenecaPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Asmanex
NovartisPreclinical
Celexa
AbbViePreclinical
Arcoxia
NovartisPreclinical
Paracetamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Asthma6 trials
Corticosteroids2 trials
Omalizumab1 trial
Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT01430403·478 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inhaled corticosteroids. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company